Alprazolam transdermal - Crescita Therapeutics

Drug Profile

Alprazolam transdermal - Crescita Therapeutics

Alternative Names: Alprazolam transdermal formulation; ZRS 101

Latest Information Update: 06 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZARS
  • Developer Crescita Therapeutics
  • Class Anxiolytics; Azoles; Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Panic disorder

Most Recent Events

  • 06 May 2016 Chemical structure information added
  • 13 May 2011 ZARS Pharma has been acquired by Nuvo Research
  • 28 Aug 2006 Preclinical trials in Panic disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top